SNTI Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

-0.473

-29.35%

-0.530

-62.41%

Estimates Revision

The market is revising Downward the revenue expectations for Senti Biosciences, Inc. (SNTI) for FY2025, with the revenue forecasts being adjusted by -25% over the past three months. During the same period, the stock price has changed by -34.32%.

Revenue Estimates for FY2025

Revise Downward

-25%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+2.54%

In Past 3 Month

Stock Price

Go Down

-34.32%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast SNTI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNTI is 10.00 USD with a low forecast of 6.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

6.00

Averages

10.00

High

12.00

Current: 0.000

Low

6.00

Averages

10.00

High

12.00

Chardan

Buy

maintain

$12 -> $13

2025-12-09

Reason

Chardan

Price Target

$12 -> $13

2025-12-09

maintain

Buy

Reason

Chardan raised the firm's price target on Senti Bio to $13 from $12 and keeps a Buy rating on the shares after the announced updated data from the ongoing Phase I study of SENTI-202 in relapsed/refractory acute myeloid leukemia. The firm believes the days shows "signals of encouraging efficacy and durability" for a broad population. However, Senti's cash runway remains an overhang on the stock, the analyst tells investors in a research note.

Leerink

Jeffrey La Rosa

Outperform

initiated

2025-11-21

Reason

Leerink

Jeffrey La Rosa

Price Target

2025-11-21

initiated

Outperform

Reason

Leerink analyst Jeffrey La Rosa initiated coverage of Senti Bio with an Outperform rating and $6 price target. The firm believes Senti's novel LogicGated gene circuit platform offers a promising solution to solve the therapeutic window problem that has plagued cell therapies pursuing cancers with "dirty" antigen targets. The company's lead clinical candidate, SENTI-202, is an elegantly designed allogeneic, or off-the-shelf, CAR-NK cell therapy in Phase 1 for relapsed or refractory acute myeloid leukemia. For Leerink, the preliminary Phase 1 dose escalation data reported to date help validate SENTI-202's Logic-Gated design and support a potentially differentiated clinical profile relative to currently available AML therapies and the industry's past attempts at developing immune cell-based therapies for the indication.

H.C. Wainwright

initiated

$12

2025-10-14

Reason

H.C. Wainwright

Price Target

$12

2025-10-14

initiated

Reason

H.C. Wainwright initiated coverage of Senti Bio with a Buy rating and $12 price target. The firm believes the company's allogeneic CAR-NK cell therapy platform has the potential to treat several cancer types including hematologic malignancies and solid tumors. It views Senti as an "underappreciated CAR-NK player with a differentiated platform with a near-term catalyst" in Q4.

Laidlaw

NULL -> Buy

initiated

2025-06-06

Reason

Laidlaw

Price Target

2025-06-06

initiated

NULL -> Buy

Reason

Laidlaw initiated coverage of Senti Bio with a Buy rating and $5 price target. Senti is an early clinical stage oncology-emphasized biotech company that focuses on a novel and differentiated CAR-NK therapy, SENTI-202, as a potential high-risk relapsed or refractory acute myeloid leukemia treatment, the analyst tells investors in a research note. The firm says the company recently reported "very promising" Phase I interim results.

Valuation Metrics

The current forward P/E ratio for Senti Biosciences Inc (SNTI.O) is -0.68, compared to its 5-year average forward P/E of -1.11. For a more detailed relative valuation and DCF analysis to assess Senti Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.11

Current PE

-0.68

Overvalued PE

0.29

Undervalued PE

-2.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.73

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.98

Undervalued EV/EBITDA

-2.44

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

19.89

Current PS

57.84

Overvalued PS

45.83

Undervalued PS

-6.04

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

SNTI News & Events

Events Timeline

No data

News

5.0

2025-12-18Globenewswire

Senti Biosciences Grants New Employee 13,680 Stock Options at $1.31 Each

5.0

2025-12-18Newsfilter

Senti Biosciences Grants New Employee 13,680 Stock Options at $1.31 Each

2.0

2025-12-10NASDAQ.COM

Post-Market Surge: Stoke Therapeutics, Alpha Tau Medical, and Compass Pathways Top Biotech Gainers

People Also Watch

Frequently Asked Questions

What is Senti Biosciences Inc (SNTI) stock price today?

The current price of SNTI is 1.11 USD — it has increased 2.78 % in the last trading day.

What is Senti Biosciences Inc (SNTI)'s business?

Senti Biosciences, Inc. and its subsidiaries is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The Company is leveraging its synthetic biology platform to engineer gene circuits into new medicines with enhanced precision and control. These gene circuits are designed to kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. Its product candidates include SENTI-202 and SENTI-301A. SENTI-202 is a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy. SENTI-301A is a multi-armed off-the-shelf healthy donor-derived chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed for the treatment of GPC3 positive tumors.

What is the price predicton of SNTI Stock?

What is Senti Biosciences Inc (SNTI)'s revenue for the last quarter?

Senti Biosciences Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Senti Biosciences Inc (SNTI)'s earnings per share (EPS) for the last quarter?

Senti Biosciences Inc. EPS for the last quarter amounts to -0.69 USD, decreased -89.06 % YoY.

What changes have occurred in the market's expectations for Senti Biosciences Inc (SNTI)'s fundamentals?

How many employees does Senti Biosciences Inc (SNTI). have?

Senti Biosciences Inc (SNTI) has 34 emplpoyees as of January 10 2026.

What is Senti Biosciences Inc (SNTI) market cap?

Today SNTI has the market capitalization of 29.18M USD.